Neoadjuvant Everolimus (RAD001)for Advanced RCC Before Cytoreductive Nephrectomy, With Correlative Tumor Studies (Protocol #: 06-08-20-01)

Trial Profile

Neoadjuvant Everolimus (RAD001)for Advanced RCC Before Cytoreductive Nephrectomy, With Correlative Tumor Studies (Protocol #: 06-08-20-01)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Feb 2016 Status changed from recruiting to discontinued due to difficulty in accrual and by the order of the cancer center, according to ClinicalTrials.gov record.
    • 01 Apr 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 01 Apr 2011 Planned end date changed from Jul 2015 to Jul 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top